News Headlines

Display #
Title
U.S. FDA to review Teva and Celltrion’s cancer biosimilar drug
Express Scripts to cover Mylan’s EpiPen, exclude rivals
New Research Shows 99 Percent of Life Science Companies Still Need to Unify Clinical Applications
Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
U.S. Senator expands opioid probe to distributors, drugmakers
Amgen gets fast FDA review for adding heart benefits to cholesterol drug label
U.S. House panel spotlights use of FDA rules to slow generic drugs
FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related disease, death
Green tea ingredient may ameliorate memory impairment, brain insulin resistance, and obesity
Boston Scientific Warns of Fluke Death Involving Its S-ICD Pacemaker
CMOs Cringe as GlaxoSmithKline Will be Cutting Its Use by 25%
Merck cyber attack will hurt profits
AbbVie’s profit beats analysts’ expectations
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
Johnson & Johnson announces encouraging first-in-human clinical data for investigational HIV preventive vaccine
AstraZeneca lung cancer failure sparks share fall
AstraZeneca and Merck establish strategic oncology collaboration
AstraZeneca, Merck Seal $8.5 Billion R&D Cancer Deal
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma
Astellas Takes a $387 Million+ Loss as It Shuts Down SoCal’s Agensys
Not-Yet Sold Tesaro Bags $340 Million Cancer Deal With Pharma Giant Takeda
Scientists find sunscreen potential in Antarctic plants
Bristol-Myers shares slump after rival’s failed study
Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin® (bevacizumab)
Americans say discussions about clinical trials should be part of standard of care
FDA Head Postpones Layoff Notices of Thousands of Employees
Obamacare repeal battle back on the Senate floor
Anthem says may exit more individual markets over Obamacare funding
GlaxoSmithKline’s new boss streamlines R&D
Safety concerns for Dynavax hep B vaccine